Innova Captab Ltd

Innova Captab Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Innova Captab Ltd

₹ 913 0.05%
24 Apr 10:07 a.m.
innovacaptab.com BSE: 544067 NSE: INNOVACAP
About

Incorporated in January 2005, Innova Captab Ltd is a pharmaceutical company is an integrated pharmaceutical company in India with a presence across the pharmaceutical value chain.[1]

Key Points

Business Profile[1]
Innova Captab Limited is an integrated pharmaceutical player with a strong presence across the pharmaceutical value chain

Website BSE NSE
  • Market Cap ₹ 5,224 Cr.
  • Current Price ₹ 913
  • High / Low ₹ 1,260 / 421
  • Stock P/E 41.0
  • Book Value ₹ 156
  • Dividend Yield 0.00 %
  • ROCE 19.0 %
  • ROE 17.0 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has delivered good profit growth of 36.5% CAGR over last 5 years

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln

Part of BSE Healthcare Nifty Total Market BSE Allcap BSE SmallCap Nifty Microcap 250

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024
242 242 241 233 283 302 263 294 318 316
211 208 214 202 242 258 225 252 268 270
Operating Profit 31 34 27 31 40 45 38 42 50 47
OPM % 13% 14% 11% 13% 14% 15% 14% 14% 16% 15%
2 3 3 1 3 2 6 2 2 4
Interest 5 6 5 5 9 7 1 0 0 0
Depreciation 3 3 3 3 5 5 3 5 5 5
Profit before tax 25 28 21 25 30 35 40 39 47 46
Tax % 24% 31% 19% 28% 24% 29% 27% 25% 25% 25%
19 20 17 18 23 25 29 29 35 34
EPS in Rs 3.91 4.08 3.59 3.66 4.77 4.39 5.02 5.15 6.12 5.98
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
356 373 411 801 926 1,081 1,192
315 322 356 704 813 927 1,015
Operating Profit 41 51 54 96 114 154 177
OPM % 11% 14% 13% 12% 12% 14% 15%
0 1 1 3 9 12 14
Interest 6 5 4 6 20 21 1
Depreciation 11 10 6 8 11 16 18
Profit before tax 25 38 46 86 92 130 171
Tax % 20% 26% 26% 25% 26% 27%
20 28 34 64 68 94 127
EPS in Rs 165.67 232.42 287.50 532.92 14.16 16.49 22.27
Dividend Payout % 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: %
5 Years: 25%
3 Years: 38%
TTM: 12%
Compounded Profit Growth
10 Years: %
5 Years: 37%
3 Years: 40%
TTM: 54%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 93%
Return on Equity
10 Years: %
5 Years: 24%
3 Years: 23%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 12 12 12 12 48 57 57
Reserves 70 98 133 197 229 774 838
72 54 46 199 237 245 261
68 81 179 167 191 240 278
Total Liabilities 223 245 370 575 704 1,316 1,435
78 73 79 183 183 358 361
CWIP 0 0 7 0 22 341 452
Investments 0 0 0 0 0 0 0
144 172 283 392 500 617 621
Total Assets 223 245 370 575 704 1,316 1,435

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
19 31 42 59 67 146
-9 -6 -20 -188 -91 -499
-9 -23 -19 125 27 361
Net Cash Flow 1 1 3 -5 3 8

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 93 85 123 97 104 97
Inventory Days 50 84 107 76 77 91
Days Payable 80 92 132 86 105 113
Cash Conversion Cycle 64 77 99 87 77 75
Working Capital Days 77 86 73 97 98 88
ROCE % 26% 28% 31% 24% 19%

Shareholding Pattern

Numbers in percentages

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
50.90% 50.90% 50.90% 50.90% 50.90% 50.90%
3.57% 1.94% 1.19% 1.01% 0.74% 0.35%
10.31% 20.78% 21.24% 20.61% 19.96% 19.77%
35.22% 26.39% 26.67% 27.48% 28.41% 29.00%
No. of Shareholders 1,39,11739,39635,11532,25436,69239,996

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls